From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

Last Updated: Thursday, October 10, 2024

Researchers performed a meta-analysis to evaluate the effectiveness and safety of 16 different neoadjuvant treatment protocols in patients with HR+ HER2- breast cancer. After evaluating data from 5,752 patients, the researchers concluded that the anthracycline-containing chemotherapy plus olaparib and anthracycline-containing chemotherapy plus nivolumab groups demonstrated superior efficacy as neoadjuvant therapy in this disease type. However, they stated that further research, especially randomized controlled trials, are necessary to validate these findings.

Frontiers in Immunology
Advertisement
News & Literature Highlights

Journal of Cachexia, Sarcopenia, and Muscle

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

European Journal of Cancer

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Cancer Letters

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

Future Oncology

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

U.S. Food and Drug Administration

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Journal of Clinical Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

Drugs

Efficacy and safety of CDK4/6 inhibitors: A focus on HR+/HER2- early breast cancer

Nature Communications

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Oncology Research and Treatment

Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany: Final results of the phase 2 multicohort INGE-B trial

Clinical Breast Cancer

Real world evidence study to assess incidence, treatment patterns, clinical outcomes, and health care resource utilization in early-stage, high-risk HER2-negative breast cancer in Alberta, Canada

Advertisement
Advertisement